Types of MHT: Pills, Patches, Gels, Creams, Pellets , A Clinical Comparison

Transdermal estrogen delivers cardiovascular neutrality that oral formulations cannot match. The ESTHER study demonstrated oral estrogen increases venous thromboembolism risk 4.5-fold while transdermal estradiol shows no increased risk (OR 0.9, 95% CI 0.4-2.1). This difference stems from hepatic first-pass metabolism, which oral routes require and transdermal routes bypass. The 2023 Menopause Society position statement explicitly recommends non-oral estradiol for women with cardiovascular risk factors. Pellet therapy, despite growing popularity, lacks randomized trial evidence for cardiovascular safety and produces estradiol levels 2-4 times higher than other formulations.

The Conversation That Never Happened

Patch, pill, pellet , her three friends were on all three different things. None of them had been told the difference in clot risk between the first two. None had been told the pellet had the thinnest evidence base.

This happens in my cardiology practice weekly. A woman arrives for cardiovascular risk assessment already taking menopausal hormone therapy. She knows she is on “bioidentical hormones.” She does not know the route of delivery changes her clot risk by a factor of four. She was never told that her pellet implant will produce estradiol levels three times higher than physiologic, with no way to reduce the dose if problems emerge.

The formulation conversation should happen before the prescription. It almost never does.

Menopausal hormone therapy is not a single intervention. It is a matrix of choices. Estrogen type. Estrogen route. Progesterone type. Progesterone route. Each combination carries distinct vascular implications. A woman on transdermal estradiol with micronized progesterone inhabits a different risk universe than a woman on oral conjugated equine estrogen with medroxyprogesterone acetate. The clinical trials that generated the data we use today, particularly the Women’s Health Initiative, tested specific formulations. Extrapolating those results to different delivery systems requires understanding the biology of why route matters.

This article provides that understanding. Every formulation option with cardiovascular data gets examined. Where evidence is strong, I will say so. Where evidence is thin, I will say that too.

Why Route Changes Everything: The First-Pass Effect

When you swallow an estrogen pill, every molecule passes through your liver before reaching systemic circulation. This is called first-pass hepatic metabolism. It is not a minor pharmacokinetic detail. It fundamentally alters what estrogen does to your body.

The liver responds to oral estrogen exposure by increasing production of clotting proteins. Prothrombin fragment 1+2 rises by 29%. Fibrinopeptide A increases by 40%. These are direct markers of activated coagulation. The liver also increases C-reactive protein synthesis by 54%, an inflammatory marker independently associated with cardiovascular events. Lobo 1994

Transdermal estrogen bypasses the portal circulation entirely. The hormone enters the bloodstream through the skin, avoiding the liver’s initial processing. The result: no significant change in clotting factors. No CRP elevation. The estrogen reaches its target tissues without first triggering hepatic protein synthesis.

The ESTHER study quantified this difference with precision. Researchers in France conducted a case-control study examining VTE risk by estrogen route. Oral estrogen showed an odds ratio of 4.5 for venous thromboembolism (95% CI 1.8-11.3). Transdermal estrogen showed an odds ratio of 0.9 (95% CI 0.4-2.1). Canonico 2007 5 / Solid

In absolute terms: baseline VTE incidence for women aged 50-59 is approximately 1-2 per 10,000 woman-years. Oral estrogen increases this to 5-10 per 10,000 woman-years. Transdermal estrogen maintains the baseline rate. For women with BMI above 30, the absolute risk with oral estrogen rises to 20-30 per 10,000 woman-years. Canonico 2008

The 2019 BMJ nested case-control study using QResearch and CPRD databases confirmed these findings in over 80,000 women. Transdermal estradiol carried significantly lower VTE risk than oral preparations across all doses. Vinogradova 2019 5 / Solid

Triglycerides tell the same story from a different angle. Oral estrogen increases triglycerides by 20-30%, a mean rise of approximately 24 mg/dL documented in the WHI estrogen-alone trial. Transdermal estradiol does the opposite, reducing triglycerides by 10-15%, a mean decrease of 15 mg/dL. For women with baseline hypertriglyceridemia above 200 mg/dL, this difference determines whether MHT is safe or contraindicated.

The Formulation Matrix: What Each Delivery System Actually Does

Transdermal Patches

The estradiol patch remains the best-studied transdermal option. Doses range from 25 to 100 mcg daily, delivering steady-state estradiol levels of 50-100 pg/mL. Application is once or twice weekly depending on formulation. Skin irritation occurs in approximately 10% of users, usually manageable with rotation of application sites.

From a cardiovascular standpoint, patches are the reference standard for “non-oral neutral.” The 2023 Menopause Society position statement explicitly recommends transdermal estradiol for women with cardiovascular risk factors or established cardiovascular disease. Faubion 2023 The 2020 International Menopause Society recommendations echo this preference.

Transdermal Gels and Sprays

Estradiol gel (applied daily to arm or thigh) and estradiol spray (applied daily to forearm) provide the same first-pass bypass as patches. Dosing is more flexible, titrated by number of pump actuations or sprays. Absorption can vary with application technique, skin thickness, and sweating.

Evidence for cardiovascular safety parallels patch data because the mechanism is identical: avoidance of hepatic first-pass metabolism. The Scarabin meta-analysis groups all transdermal routes together when calculating VTE risk, finding consistently neutral results. Scarabin 2018 4 / Promising

Vaginal Estrogen

Low-dose vaginal estradiol (10-25 mcg tablets, rings, or creams) produces minimal systemic absorption. Serum estradiol levels remain in the postmenopausal range, below 20 pg/mL. This route treats genitourinary syndrome of menopause, including vaginal dryness and urinary symptoms, without systemic cardiovascular or thrombotic effects.

Vaginal estrogen is not MHT in the systemic sense. It is local therapy. It does not address vasomotor symptoms or bone protection. It also does not require progesterone for endometrial protection at standard low doses.

Oral Estrogen

Conjugated equine estrogens (Premarin) and oral estradiol tablets remain widely prescribed despite the hepatic first-pass problem. Oral estrogen effectively treats vasomotor symptoms and prevents bone loss. The WHI data, with all its complexity, tested oral conjugated equine estrogens.

For women without VTE risk factors, without hypertriglyceridemia, without hepatic disease, oral estrogen remains an option. But “without risk factors” describes fewer women than prescribers often assume. The 2020 IMS recommendations specify that non-oral routes should be preferred when cardiovascular or VTE risk is elevated. Baber 2020

The Vaginal Ring for Systemic MHT

A higher-dose vaginal ring (Femring, releasing 50-100 mcg/day) does produce systemic estradiol levels and treats vasomotor symptoms. Unlike patches, the ring requires only once-every-three-months placement. Unlike low-dose vaginal estrogen, it does require progesterone for uterine protection.

Cardiovascular data specific to systemic-dose vaginal rings are limited. The route bypasses hepatic first-pass, suggesting a similar profile to patches and gels. But direct comparative trials are lacking.

The Pellet Problem: Popularity Outpaces Evidence

Subcutaneous hormone pellets, typically containing estradiol and often testosterone, are inserted under the skin every 3-4 months. They release hormone continuously as the pellet dissolves. The market has grown substantially, driven by cash-pay clinics and direct-to-consumer marketing.

Here is what the evidence actually shows.

Pellets produce supraphysiologic estradiol levels. A systematic review found mean peak estradiol levels of 237 pg/mL with pellet therapy, compared to 50-100 pg/mL with transdermal patches. Some women reach levels above 400 pg/mL. ACOG 2023 5 / Solid

No randomized controlled trials have evaluated pellet therapy for cardiovascular safety outcomes. None. The ACOG 2023 Clinical Consensus statement explicitly addresses this gap: pellet therapy lacks the evidence base that FDA-approved formulations possess. The Menopause Society’s 2023 position statement does not recommend pellets for standard MHT.

The dosing problem is unfixable. Once a pellet is implanted, you cannot reduce the dose. If a woman develops breast tenderness, mood changes, or elevated estradiol levels, she must wait months for the pellet to dissolve. With patches or gels, she can stop immediately or adjust within days.

Testosterone pellets compound the uncertainty. Many pellet regimens include testosterone at doses that produce serum levels above the female physiologic range. The cardiovascular effects of supraphysiologic testosterone in women are unknown. Theoretical concerns include adverse lipid effects and erythrocytosis.

Women don’t die from what they have. Women die from what they hold. And some women are holding hormone formulations chosen for marketing reasons rather than evidence reasons.

This does not mean pellets definitively cause harm. It means we do not know, and the theoretical concerns are legitimate. When FDA-approved transdermal options exist with established safety profiles, choosing an understudied alternative requires explicit informed consent about that uncertainty.

The Progesterone Question: Synthetic vs. Micronized

Women with a uterus require progesterone or a progestin to prevent endometrial hyperplasia from unopposed estrogen. The choice of progestogen is not cardiovascular-neutral.

The PEPI trial randomized women to different MHT regimens and measured lipid and hemostatic outcomes. Medroxyprogesterone acetate (MPA), the synthetic progestin used in the WHI, reduced HDL cholesterol by 15%. Micronized progesterone preserved the HDL benefit of estrogen. The difference was statistically and clinically significant.

Thrombotic risk also differs. The ESTHER study found that progestins derived from norpregnane compounds increased VTE risk when combined with oral estrogen. Micronized progesterone showed no increased risk. The Scarabin meta-analysis confirmed this pattern: progestogen type matters for VTE.

Micronized progesterone (Prometrium) is chemically identical to endogenous progesterone. It is metabolized to allopregnanolone, which has anxiolytic effects. Some women report improved sleep. The 2023 Menopause Society position statement indicates micronized progesterone as a preferred option for cardiovascular-risk women.

Progestogen route also matters. Vaginal progesterone provides endometrial protection with minimal systemic absorption. The levonorgestrel intrauterine system provides local endometrial protection with minimal systemic progestin exposure. Both options avoid the systemic effects of oral synthetic progestins.

Compounded vs. FDA-Approved: The Same Molecule, Different Oversight

“Bioidentical” describes hormones chemically identical to human hormones. Estradiol is bioidentical. Micronized progesterone is bioidentical. Both are available as FDA-approved products manufactured under strict quality standards.

Compounded bioidentical hormones contain the same molecules but are prepared by compounding pharmacies without FDA oversight. The distinction matters for three reasons.

First, potency consistency. Studies of compounded hormone preparations show significant variability from labeled dose, some as high as 34% deviation. FDA-approved products must meet strict potency standards.

Second, safety monitoring. FDA-approved products undergo post-marketing surveillance. Adverse events are tracked and reported. Compounded products have no such system.

Third, evidence base. Clinical trials use FDA-approved formulations. When we cite the ESTHER study’s finding that transdermal estradiol is VTE-neutral, we are citing data generated with standardized, quality-controlled preparations. Extrapolating those findings to compounded products requires assuming equivalent bioavailability, which may not hold.

The ACOG 2023 consensus statement recommends FDA-approved hormone therapy over compounded preparations except in cases of allergy to a component of the FDA-approved product.

Choosing a Formulation: The Clinical Framework

I call this framework the Route-Risk-Response approach.

Route Assessment

Does this woman have any VTE risk factor? Prior clot, Factor V Leiden, obesity, immobility, recent surgery, active cancer, age over 60? If yes, transdermal is strongly preferred. Does she have hypertriglyceridemia above 200 mg/dL? Transdermal. Hepatic disease or gallbladder disease? Transdermal.

Risk Stratification

Beyond VTE, consider overall cardiovascular risk. The 2023 Menopause Society position statement provides guidance: for women with cardiovascular disease or multiple risk factors, transdermal estradiol with micronized progesterone (if uterus present) represents the lowest-risk MHT option.

Response Monitoring

Check symptom response at 8-12 weeks. If vasomotor symptoms persist, dose adjustment is simpler with gels and sprays than with patches. Check estradiol levels if response is inadequate. Therapeutic target is generally 50-100 pg/mL.

For progesterone, cyclic dosing (200 mg for 12-14 days monthly) or continuous dosing (100 mg nightly) are both acceptable. The levonorgestrel IUD is an excellent alternative for women who tolerate it.

What to Bring to Your Next Appointment

The clinical conversation should cover these specific points:

Your VTE risk factors, listed explicitly: BMI, smoking status, family history of clots, personal history, planned surgeries, current immobility.

Your triglyceride level from recent bloodwork. If above 150, transdermal becomes more important. If above 200, oral estrogen is relatively contraindicated.

Your preference for application frequency. Twice-weekly patch, daily gel, once-every-three-months ring. Adherence matters more than theoretical differences between transdermal formats.

Your questions about progesterone options. If you have a uterus, you need progesterone or a progestin. Ask specifically about micronized progesterone versus synthetic progestins and why your prescriber recommends what they recommend.

If pellets have been offered, ask these questions: What is the evidence for cardiovascular safety? What happens if my estradiol level is too high? How will we adjust the dose if needed?

At your next visit, ask for these four tests by name: estradiol level, FSH, lipid panel including triglycerides, and complete metabolic panel. Print this article and bring it with you.

Frequently Asked Questions

Which form of estrogen has the lowest blood clot risk?

Transdermal estrogen, delivered via patch, gel, or spray, demonstrates no increased VTE risk in multiple large studies. The ESTHER study found oral estrogen increased clot risk 4.5-fold (OR 4.5, 95% CI 1.8-11.3) while transdermal showed no increased risk (OR 0.9, 95% CI 0.4-2.1). The 2019 BMJ nested case-control study confirmed this finding across over 80,000 women. For women with any VTE risk factors, including obesity, age over 60, immobility, or family history, transdermal delivery is the clear evidence-based choice. The first-pass hepatic bypass eliminates the increased coagulation factor synthesis that creates oral estrogen’s thrombotic risk.

Are hormone pellets safe for heart health?

Pellets lack cardiovascular safety data from randomized controlled trials. The ACOG 2023 Clinical Consensus statement explicitly notes this evidence gap. Pellets produce supraphysiologic estradiol levels averaging 237 pg/mL, compared to 50-100 pg/mL for patches, with some women exceeding 400 pg/mL. Once implanted, dose cannot be reduced if problems emerge. Neither the Menopause Society nor ACOG recommends pellets for standard menopausal hormone therapy. If you are considering pellets, understand that you are choosing a formulation without the evidence base that FDA-approved transdermal options possess. Ask your provider to explain why pellets rather than patches for your specific situation.

Does the type of progesterone matter for heart risk?

Yes, substantially. The PEPI trial demonstrated that medroxyprogesterone acetate, the synthetic progestin used in the WHI, reduced HDL cholesterol by 15%. Micronized progesterone preserved HDL. The ESTHER study found that certain synthetic progestins increased VTE risk while micronized progesterone showed no increased risk. The 2023 Menopause Society position statement identifies micronized progesterone as a preferred option for women with cardiovascular risk factors. Micronized progesterone is available as FDA-approved Prometrium. The levonorgestrel IUD provides an alternative for endometrial protection with minimal systemic progestin exposure.

Should I switch from pills to patches if I have high triglycerides?

Yes. Oral estrogen increases triglycerides by 20-30%, with mean increases of approximately 24 mg/dL documented in clinical trials. Transdermal estradiol reduces triglycerides by 10-15%, with mean decreases of 15 mg/dL. For women with baseline triglycerides above 200 mg/dL, oral estrogen is relatively contraindicated because further triglyceride elevation increases pancreatitis risk and contributes to cardiovascular risk. The switch to transdermal eliminates hepatic first-pass metabolism, which is the mechanism driving the triglyceride effect. Discuss the transition with your prescriber. Most women can switch directly to an equivalent transdermal dose.

What is the difference between FDA-approved and compounded bioidentical hormones?

Both contain chemically identical molecules, typically estradiol and micronized progesterone. The difference is manufacturing oversight. FDA-approved products undergo standardized production with strict potency testing, batch consistency requirements, and post-marketing safety surveillance. Compounded formulations from specialty pharmacies have no such oversight. Studies document compounded products varying by up to 34% from labeled dose. When clinical trials demonstrate that transdermal estradiol is VTE-neutral, they use standardized FDA-approved products. The ACOG 2023 consensus statement recommends FDA-approved therapy over compounded preparations except when allergy to an FDA product component necessitates compounding.